LIAN Projected Dividend Yield

ADS (Sponsored)/LianBio ( NASDAQ : LIAN )

LianBio is a biopharmaceutical company. Co. has assembled a pipeline of various product candidates across five different therapeutic areas. Co.'s late-stage development pipeline is led by mavacamten, TP-03 and NBTXR3. Co. develops mavacamten, an oral therapy for the treatment of obstructive hypertrophic cardiomyopathy. Co. has partnered with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 (lotilaner ophthalmic solution), an eye solution for the treatment of Demodex blepharitis. Co. has partnered with Nanobiotix S.A. to develop and commercialize NBTXR3, a radiosensitizer designed to be injected directly into a malignant tumor prior to standard radiotherapy.

11 YEAR PERFORMANCE RESULTS